JP2019517587A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517587A5 JP2019517587A5 JP2019516086A JP2019516086A JP2019517587A5 JP 2019517587 A5 JP2019517587 A5 JP 2019517587A5 JP 2019516086 A JP2019516086 A JP 2019516086A JP 2019516086 A JP2019516086 A JP 2019516086A JP 2019517587 A5 JP2019517587 A5 JP 2019517587A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- administered
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 12
- 229960005084 CALCITRIOL Drugs 0.000 claims description 12
- PWBHUSLMHZLGRN-UHFFFAOYSA-N ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 claims description 12
- 229940046008 Vitamin D Drugs 0.000 claims description 12
- 229930003316 Vitamin D Natural products 0.000 claims description 12
- 235000020964 calcitriol Nutrition 0.000 claims description 12
- 239000011612 calcitriol Substances 0.000 claims description 12
- 235000019166 vitamin D Nutrition 0.000 claims description 12
- 239000011710 vitamin D Substances 0.000 claims description 12
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229960005069 Calcium Drugs 0.000 claims description 8
- 235000001465 calcium Nutrition 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 201000005787 hematologic cancer Diseases 0.000 claims description 7
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 6
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 6
- 239000004067 bulking agent Substances 0.000 claims description 4
- 230000004094 calcium homeostasis Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 230000001502 supplementation Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- -1 tautomer Substances 0.000 claims description 3
- 230000002730 additional Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 48
- 230000000306 recurrent Effects 0.000 claims 1
- 230000000155 isotopic Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662346344P | 2016-06-06 | 2016-06-06 | |
US62/346,344 | 2016-06-06 | ||
PCT/US2017/035892 WO2017214014A1 (en) | 2016-06-06 | 2017-06-05 | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019517587A JP2019517587A (ja) | 2019-06-24 |
JP2019517587A5 true JP2019517587A5 (US07981874-20110719-C00313.png) | 2020-07-30 |
JP7163281B2 JP7163281B2 (ja) | 2022-10-31 |
Family
ID=60482040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019516086A Active JP7163281B2 (ja) | 2016-06-06 | 2017-06-05 | 2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドによる血液系悪性腫瘍の治療 |
Country Status (15)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
CA3010801A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
US11535603B1 (en) | 2016-09-30 | 2022-12-27 | Deuterx, Llc | Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same |
CN113347974A (zh) * | 2018-12-31 | 2021-09-03 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的组合物和使用方法 |
PE20221155A1 (es) * | 2019-11-05 | 2022-07-18 | Celgene Corp | Terapia de combinacion con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida |
JP2023505254A (ja) | 2019-12-06 | 2023-02-08 | セルジーン コーポレーション | 2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドを製造するための方法 |
CN115515582A (zh) * | 2020-03-16 | 2022-12-23 | 细胞基因公司 | 急性髓系白血病的组合疗法 |
PE20230847A1 (es) * | 2020-09-23 | 2023-05-23 | St Jude Childrens Res Hospital Inc | Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como modulares de la proteina cereblon |
KR20240066906A (ko) * | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005515996A (ja) * | 2001-12-03 | 2005-06-02 | ノバセア インコーポレイティッド | 活性型ビタミンd化合物を含む薬学的組成物 |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US20090175869A1 (en) * | 2007-05-31 | 2009-07-09 | Ascenta Therapeutics, Inc. | Pulsatile Dosing of Gossypol for Treatment of Disease |
CA2762458C (en) | 2009-05-20 | 2018-08-28 | Hybrigenics Sa | New therapeutical uses of inecalcitol |
BR112014010417A2 (pt) * | 2011-11-01 | 2014-11-18 | Celgene Corp | Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina |
ES2785203T3 (es) | 2013-12-05 | 2020-10-06 | Hoffmann La Roche | Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA) |
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
AR107321A1 (es) | 2016-01-08 | 2018-04-18 | Celgene Corp | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos |
JP7071922B2 (ja) | 2016-01-08 | 2022-05-19 | セルジーン コーポレイション | 2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドの固体形態、ならびにそれらの薬学的組成物及び使用 |
US10052315B2 (en) | 2016-01-08 | 2018-08-21 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
-
2017
- 2017-06-05 CN CN201780035323.6A patent/CN109414436A/zh active Pending
- 2017-06-05 WO PCT/US2017/035892 patent/WO2017214014A1/en unknown
- 2017-06-05 AU AU2017278114A patent/AU2017278114B2/en active Active
- 2017-06-05 US US15/614,434 patent/US10245258B2/en active Active
- 2017-06-05 CN CN202211003162.1A patent/CN115282149A/zh active Pending
- 2017-06-05 EP EP17810774.4A patent/EP3463358A4/en active Pending
- 2017-06-05 BR BR112018075206-1A patent/BR112018075206A2/pt unknown
- 2017-06-05 JP JP2019516086A patent/JP7163281B2/ja active Active
- 2017-06-05 SG SG11201809501PA patent/SG11201809501PA/en unknown
- 2017-06-05 KR KR1020187035780A patent/KR20190015300A/ko not_active IP Right Cessation
- 2017-06-05 CA CA3026396A patent/CA3026396A1/en active Pending
- 2017-06-05 MX MX2018015120A patent/MX2018015120A/es unknown
- 2017-06-05 EA EA201892746A patent/EA201892746A1/ru unknown
- 2017-06-05 IL IL262565A patent/IL262565B/en unknown
-
2018
- 2018-10-24 ZA ZA2018/07105A patent/ZA201807105B/en unknown
- 2018-12-06 CL CL2018003499A patent/CL2018003499A1/es unknown
-
2019
- 2019-02-13 US US16/275,234 patent/US20190175573A1/en not_active Abandoned
-
2020
- 2020-07-02 US US16/920,267 patent/US11590117B2/en active Active
-
2023
- 2023-01-25 US US18/101,499 patent/US20230158009A1/en active Pending
- 2023-04-06 AU AU2023202159A patent/AU2023202159A1/en active Pending